The TZD insulin sensitizer clue provides a new route into diabetes drug discovery

Bibliography

• Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl 1):S1–S93.
   PubMed Web of Science ®Google Scholar
• Gale AM. Commentary: the hedgehog and the fox: Sir Harold Himsworth (1905–93). Int J Epidemiol. 2013;42:1602–1607.
   PubMed Web of Science ®Google Scholar
• Turner LW, Nartey D, Stafford RS, et al. Ambulatory treatment of type 2 diabetes in the US, 1997–2012. Diabetes Care. 2014;37:985–992.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011;34:S202–09.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Aschner P, Del Prato S, et al. and on behalf of the Global Partnership for Effective Diabetes Management. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res. 2013;10:397–409.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–1046.
   PubMed Web of Science ®Google Scholar
• Beagley J, Guariguata L, Weil C, et al. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150–160.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes. 1988;37:667–687.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;12:1595–1607.
   Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194.
   PubMed Web of Science ®Google Scholar
• Stewart MW, Humphriss DB, Berrish TS, et al. Features of syndrome X in first-degree relatives of NIDDM patients. Diabetes Care. 1995;18:1020–1022.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of Type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar

•• Excellent discussion of the pathophysiology of type 2 diabetes

• Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350–357.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893–2898.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066–3072.
   PubMed Web of Science ®Google Scholar
• Choudhury J, Sanyal AJ. Insulin resistance in NASH. Front Biosci. 2005;10:1520–1533.
   PubMed Web of Science ®Google Scholar
• De la Monte SM. Alzheimer’s is Type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2:1101–1113.
   PubMedGoogle Scholar

• Good review of data supporting a connection between diabetes and AD

• Sohda T, Meguro K, Kawamatsu Y. Studies on antidiabetic agents. IV. Synthesis and activity of the metabolites of 5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4-thiazolidinedione (ciglitazone). Chem Pharm Bull. 1984;32:2267–2278.
   PubMed Web of Science ®Google Scholar
• Chang AY, Wyse BM, Gilchrist BJ, et al. Ciglitizone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes. 1983;32:830–838.
   PubMed Web of Science ®Google Scholar
• Sohda T, Momose Y, Meguro K, et al. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung. 1990;40:37–42.
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549–1558.
   PubMed Web of Science ®Google Scholar
• Colca JR, Wyse BM, Sawada G, et al. Ciglitazone, a hypoglycemic agent: early effects on the pancreatic islets of ob/ob mice. Metabolism. 1988;37(3):276–280.
   PubMed Web of Science ®Google Scholar
• Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care. 1992;15:1075–1078.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. Thiazolidinediones today. Br J Diab Vasc Dis. 2001;1:7–13.
   Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.
   PubMed Web of Science ®Google Scholar

• Good review of early TZD data

• King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care. 2000;23:557.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Hamman RF, Edelstein SL, et al. Diabetes prevention program research group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes. 2005;54:1150–1156.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338:916–917.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in Type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25:815–821.
   PubMed Web of Science ®Google Scholar
• Bernlohr DA, Bolanowski MA, Kelly TJ Jr, et al. Evidence for an increase in transcription of specific mRNAs during differentiation of 3T3-L1 preadipocytes. J Biol Chem. 1985;260:5563–5567.
   PubMed Web of Science ®Google Scholar
• Christy RJ, Kaestner KH, Geiman DE, et al. CCAAT/enhancer binding protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc Natl Acad Sci USA. 1991;88:2593–2597.
   PubMed Web of Science ®Google Scholar
• Graves RA, Tontonoz P, Spiegelman BM. Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. Mol Cell Biol. 1992;12:1202–1208.
   PubMed Web of Science ®Google Scholar
• Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol. 1992;41:393–398.
   PubMed Web of Science ®Google Scholar
• Kletzien RF, Foellmi LA, Harris PK, et al. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol. 1992;42:558–562.
   PubMed Web of Science ®Google Scholar
• Harris PK, Kletzien RF. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol Pharmacol. 1994;45:439–445.
   PubMed Web of Science ®Google Scholar
• Lehmann JH, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR). J Biol Chem. 1995;270:12953–12956.
   PubMed Web of Science ®Google Scholar
• Shao D, Lazar MA. Peroxisome proliferator activated receptor {gamma}, CCAAT/enhancer-binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem. 1997;272:21473–21478.
   PubMed Web of Science ®Google Scholar
• Lazar MA. Becoming fat. Genes Dev. 2002;16:1–5.
   PubMed Web of Science ®Google Scholar
• Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor. J Pharmacol Exp Ther. 1998;284:751–759.
   PubMed Web of Science ®Google Scholar
• Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996;39(3):665–668.
   PubMed Web of Science ®Google Scholar
• Leff T, Reed JE. The antidiabetic PPAR.Gamma ligands: an update on compounds in development. Curr Med Chem Immunol Endocr Metab Agents. 2002;2:33–47.
   Google Scholar
• Sorbera LA, Leeson PA, Martin L, et al. Farglitazar antidiabetic PPAR {gamma} agonist. Drugs Future. 2001;26:354–363.
   Web of Science ®Google Scholar
• Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trend Endocrinol Metab. 2000;11:362–368.
   PubMed Web of Science ®Google Scholar
• Henry RR, Erickson D, Ciaraldi TP. PPAR {gamma} agonists and the future for insulin sensitizers: A report of a debate and presentations on the subject at the 72nd scientific sessions of the American diabetes association; 2012 June 8-12, Philadelphia. Br J Diabetes Vasc Dis. 2012;12:206–210.
   Google Scholar
• Feinstein DL, Spagnolo A, Akar C, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol. 2005;70:177–188.
   PubMed Web of Science ®Google Scholar

•• Good review of direct effects of TZDs on mitochondrial function

• Colca JR. Insulin sensitizers may prevent metabolic inflammation. Biochem Pharmacol. 2006;72(2):125–131.
   PubMed Web of Science ®Google Scholar
• Colca JR, Kletzien RF. What has prevented the expansion of insulin sensitisers? Expert Opin Investig Drugs. 2006;15(3):205–210.
   PubMed Web of Science ®Google Scholar

• Review of the status of TZD development up to 2006

• Colca JR, McDonald WG, Waldon DJ, et al. Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab. 2004;286:252–260.
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Cavey GS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One. 2013;8(5):e61551–10.
   PubMed Web of Science ®Google Scholar

•• Identification of the new mitochondrial target for TZDs

• Colca JR, McDonald WG, Kletzien RF. Mitochondrial target of thiazolidinediones. Diabetes, Obes Metab. 2014;16(11):1048–1054.
   PubMed Web of Science ®Google Scholar
• Divakaruni AS, Wiley SE, Rogers GW, et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci. 2013;110:5422–5427.
   PubMed Web of Science ®Google Scholar
• Vigueira PA, McCommis KS, Schweitzer GG, et al. Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion. Cell Rep. 2014;7(6):2042–2053.
   Web of Science ®Google Scholar
• McCommis KS, Chen Z, Fu X, et al. Loss of mitochondrial pyruvate carrier 2 in liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab. 2015;22:1–13.
   PubMed Web of Science ®Google Scholar

•• First paper on liver specific knock out of mpc2, key component of mTOT

• Bender T, Pena G, Martinou J-C. Regulation of mitochondrial pyruvate uptake by alternative pyruvate carrier complexes. Embo. 2015;34:911–924.
   PubMed Web of Science ®Google Scholar
• Yang C, Ko B, Hensley CT, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014;56:414–424.
   PubMed Web of Science ®Google Scholar
• Vacanti NM, Divakaruni AS, Green CR, et al. Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol Cell. 2014;56:425–435.
   PubMed Web of Science ®Google Scholar
• Perry RJ, Camporez J-PG, Kursawe R. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160:745–758.
   PubMed Web of Science ®Google Scholar
• Ochocki JD, Simon MC. Nutrient-sensing pathways and metabolic regulation in stem cells. J Cell Biol. 2013;203:23–33.
   PubMed Web of Science ®Google Scholar
• Shyh-Chang N, Daley GQ, Cantley LC. Stem cell metabolism in tissue development and aging. Development. 2013;140(12):2535–2547.
   PubMed Web of Science ®Google Scholar

• Excellent overview of the effects of metabolism on controlling stem cell fate

• LeBrasseur NK, Kelly M, Tsao T-S, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab. 2006;291:E175–81.
   PubMed Web of Science ®Google Scholar
• He G, Sung YM, DiGiovanni J, et al. Thiazolidinediones inhibit insulin-like growth factor1–induced activation of p70S6 kinase and suppress insulin-like growth factor1 tumor-promoting activity. Cancer Res. 2006;66:1873–1878.
   PubMed Web of Science ®Google Scholar
• Hann S, Zheng Y, Roman J. Rosiglitazone, and agonist of PPARγ, inhibits non-small cell carcinoma cell proliferation in part through activation of tumor sclerosis complex-2. PPAR Res. 2007;2007:8. Article ID 29632.
   Google Scholar
• Vyawahare NS, Bansode VJ, Munjal NB. “The future magic bullet”: a review of pharmacological activities of ethyl pyruvate and its derivatives. Curr Drug Ther. 2012;7:144–149.
   Google Scholar
• Colca JR, Tanis SP, McDonald WG, et al. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Exp Opin Invest Drugs. 2013;23:1–7.
   PubMed Web of Science ®Google Scholar

• Review of new TZD insulin sensitizers

• Colca JR, VanderLugt JT, Adams WJ, et al. Clinical proof of concept with MSDC-0160, a prototype mTOT modulating insulin sensitizer. Clin Pharmacol Ther. 2013;93:352–359.
   PubMed Web of Science ®Google Scholar

•• Clinical proof of concept with an isomer of one of the pioglitazone metabolites

• Chen Z, Vigueira PA, Chambers KT, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor-sparing thiazolidinedione. J Biol Chem. 2012;287:23537–23548.
   PubMed Web of Science ®Google Scholar

•• Strongest evidence for PPAR-independent effects of TZDs including direction action in hepatocytes

• Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature. 2010;466(7305):451–456.
   PubMed Web of Science ®Google Scholar
• Choi SS, Kim ES, Koh M, et al. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity. J Biol Chem. 2014;289(38):26618–26629.
   PubMed Web of Science ®Google Scholar
• Banks AS, McAllister FE, Camporez JP, et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ. Nature. 2015;517(7534):391–395.
   PubMed Web of Science ®Google Scholar
• Walkey CJ, Spiegelman BM. A functional peroxisome proliferator-activated receptor-gamma ligand-binding domain is not required for adipogenesis. J Biol Chem. 2008;283(36):24290–24294.
   PubMed Web of Science ®Google Scholar
• Cho DH, Lee EJ, Kwon KJ, et al. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J Neurochem. 2013;126(5):685–695.
   PubMed Web of Science ®Google Scholar
• Chen J, Li S, Sun W, et al. Thiazolidinediones and the promise of insulin sensitization in Type 2 diabetes. Cell Metab. 2014;20(4):573–591.
   PubMed Web of Science ®Google Scholar

•• Excellent review of this literature including both TZDs and non-TZDs

• Chen J, Li S, Sun W, et al. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. PLoS One. 2015; 14;10(4):e0123864.
   Google Scholar
• Zhang H, Guan M, Townseld KL. MicroRNA-455 regulated brown adipogeneis via a novel HIF1an-AMPK-PGC1a signaling network. EMBO Rep. 2015. doi:10.15252/embr.201540837.
   Web of Science ®Google Scholar
• Ryder REJ. Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimal management of diabetes. Br J Diab Vasc Dis. 2011;11:113–120.
   Google Scholar

•• Best clinical case for the use of pioglitazone in the treatment of type 2 diabetes

• Fukunaga T, Zou W, Rohatgi N, et al. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J Bone Miner Res. 2014;30:481–488.
   Web of Science ®Google Scholar
• Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015;17(3):268–275.
   PubMed Web of Science ®Google Scholar
• Willette A, Modanlo N, Kapogiannis D. Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer’s disease. Diabetes. 2015;64:1933–1940.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neur. 2015. doi:10.1002/ana.24439.
   PubMed Web of Science ®Google Scholar
• Shah RC, Matthews DC, Andrews RD, et al. An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer’s disease. Curr Alz Res. 2014;11:564–573.
   PubMed Web of Science ®Google Scholar
• Rohatgi N, Aly H, Marshall CA, et al. Novel insulin sensitizer modulates nutrient sensitizing pathways and maintains β–cell phenotype in human islets. PLoS One. 2013;8:e62012, 1–13.
   Web of Science ®Google Scholar

• Best evidence for a direct effect of TZDs on human islets in culture

• Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol. 2013;10:676–685.
   PubMed Web of Science ®Google Scholar
• Cusi K. Management of NAFLD/NASH in patients with T2DM: new concepts and future directions. Presented at American Diabetes Association Annual Meeting; 2014 Jun 13–17; San Francisco (CA).
   Google Scholar
• Jun HJ, Kim J, Hoang MH, et al. Hepatic lipid accumulation alters global histone h3 lysine 9 and 4 trimethylation in the peroxisome proliferator-activated receptor alpha network. PLoS One. 2012;7(9):e44345.
   PubMed Web of Science ®Google Scholar
• Shaik MM, Gan SH, Kamal MA. Epigenomic approach in understanding Alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets. 2014;13(2):283–289.
   PubMed Web of Science ®Google Scholar

• An indication of where to begin looking for common epigenomic control mechanisms in diabetes and AD